Last reviewed · How we verify
Ciamatil (CYAMEMAZINE)
Ciamatil (generic name: CYAMEMAZINE) is a cyamemazine drug. It is currently in Phase 2 development.
Ciamatil works by blocking the 5-HT2A receptor, a protein that helps regulate mood and other psychological processes.
Ciamatil is a small molecule modality. It is also known by other names, including CIAMEMAZINA, CYAMEMAZINE, FL-6229, RP 7204, and RP-7204.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CYAMEMAZINE |
|---|---|
| Drug class | cyamemazine |
| Target | 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your brain has a 'volume control' for emotions and thoughts. The 5-HT2A receptor is like a dial that can turn up or down the volume of these feelings. By blocking this receptor, Ciamatil helps reduce excessive or overwhelming emotions, which can be beneficial for people with certain psychiatric conditions.
Approved indications
Common side effects
- Coma
- Poisoning deliberate
- Drug abuse
- Somnolence
- Miosis
- Toxicity to various agents
- Altered state of consciousness
- Hepatocellular injury
- Asphyxia
- Suicide attempt
- Rhabdomyolysis
- Extrapyramidal disorder
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ciamatil CI brief — competitive landscape report
- Ciamatil updates RSS · CI watch RSS
Frequently asked questions about Ciamatil
What is Ciamatil?
How does Ciamatil work?
What is the generic name of Ciamatil?
What drug class is Ciamatil in?
What development phase is Ciamatil in?
What are the side effects of Ciamatil?
What does Ciamatil target?
Related
- Drug class: All cyamemazine drugs
- Target: All drugs targeting 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing